“But even if solo antibodies or cocktails show early signs of efficacy, other risks could come into play. For one, the treatments could backfire in a phenomenon called antibody-dependent enhancement (ADE), in which a virus takes advantage of antibodies to enhance infection.”
“Antibody-dependent enhancement (ADE) of disease is a general concern for the development of antibody therapies because the mechanisms that underlie antibody protection against any virus have a theoretical potential to amplify the infection or trigger harmful immunopathology.”
WORRIED—you almost **never ever** give someone a clinically untested drug like @Regeneron’s polyclonal antibody drug—unless it’s for compassionate use for someone severely ill, or you’re crazy. Right @VincentRK? This smacks of utter craziness or desperation. #COVID19 #TrumpCovid t.co/Es0SaWA0ac
— Eric Feigl-Ding (@DrEricDing) October 2, 2020
No surprise. That would be the fastest way to dispatch him.
You don't give Regeneron to someone who already has antibodies. Surely they know this. 🤦♂️
— Chelsea Belle (@verycosmic) October 3, 2020
He'll be lucky to make it to Tuesday. He's gone rapidly downhill. ADE will do that.
— Adam Gaertner (@veryvirology) October 3, 2020
CNN asked a crap ton of questions from researchers for UPMC asking the head of Regeneron why they are using the president as a guinea pig–
— Catia Lookin (@CatiaLookin) October 3, 2020